BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25537198)

  • 1. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond.
    Xu S; Rouzer CA; Marnett LJ
    IUBMB Life; 2014 Dec; 66(12):803-11. PubMed ID: 25537198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding Network.
    Xu S; Hermanson DJ; Banerjee S; Ghebreselasie K; Clayton GM; Garavito RM; Marnett LJ
    J Biol Chem; 2014 Mar; 289(10):6799-6808. PubMed ID: 24425867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inducible microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitors derived from an oxicam template.
    Wang J; Limburg D; Carter J; Mbalaviele G; Gierse J; Vazquez M
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1604-9. PubMed ID: 20144869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Possibilities of individual choice of NSAIDs on the example of the oxicam class, taking into account clinical and pharmacological characteristics].
    Putilina MV; Teplova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7):36-41. PubMed ID: 35904290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microsomal prostaglandin E2 synthase: a safer target than cyclooxygenases?
    Timmers L; Pasterkamp G; de Kleijn DP
    Mol Interv; 2007 Aug; 7(4):195-9, 180. PubMed ID: 17827439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of microsomal prostaglandin E synthase 1 inhibitors.
    Korotkova M; Jakobsson PJ
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):64-9. PubMed ID: 24138533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of anti-inflammatory drugs targeted against prostaglandin-related molecules].
    Sato T; Nakajima T; Yamano Y
    Nihon Rinsho; 2010 Oct; 68(10):1835-9. PubMed ID: 20954326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.
    Mbalaviele G; Pauley AM; Shaffer AF; Zweifel BS; Mathialagan S; Mnich SJ; Nemirovskiy OV; Carter J; Gierse JK; Wang JL; Vazquez ML; Moore WM; Masferrer JL
    Biochem Pharmacol; 2010 May; 79(10):1445-54. PubMed ID: 20067770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzymatic probing of model lipid membranes: phospholipase A2 activity toward monolayers modified by oxicam NSAIDs.
    Czapla K; Korchowiec B; Orlof M; Magnieto JR; Rogalska E
    J Phys Chem B; 2011 Jul; 115(29):9290-8. PubMed ID: 21682312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The selective inhibition of cyclooxygenase isoforms: a new approach to the search for effective and safe nonsteroidal anti-inflammatory drug agents].
    Viktorov AP
    Lik Sprava; 1997; (5):106-11. PubMed ID: 9491713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol.
    Rörsch F; Wobst I; Zettl H; Schubert-Zsilavecz M; Grösch S; Geisslinger G; Schneider G; Proschak E
    J Med Chem; 2010 Jan; 53(2):911-5. PubMed ID: 20025212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation.
    Xu D; Rowland SE; Clark P; Giroux A; Côté B; Guiral S; Salem M; Ducharme Y; Friesen RW; Méthot N; Mancini J; Audoly L; Riendeau D
    J Pharmacol Exp Ther; 2008 Sep; 326(3):754-63. PubMed ID: 18524979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation-related disorders.
    Koeberle A; Werz O
    Biochem Pharmacol; 2015 Nov; 98(1):1-15. PubMed ID: 26123522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward the management of inflammation: recent developments of mPGES-1 inhibitors.
    Dallaporta M; Pecchi E; Thirion S; Jean A; Troadec JD
    Recent Pat CNS Drug Discov; 2010 Jan; 5(1):70-80. PubMed ID: 19751209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, COX-1/2 inhibition and antioxidant activities of new oxicam analogues designed as potential chemopreventive agents.
    Szczęśniak-Sięga B; Gębczak K; Gębarowski T; Maniewska J
    Acta Biochim Pol; 2018; 65(2):199-207. PubMed ID: 29906298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unusual coordinating behavior by three non-steroidal anti-inflammatory drugs from the oxicam family towards copper(II). Synthesis, X-ray structure for copper(II)-isoxicam, -meloxicam and -cinnoxicam-derivative complexes, and cytotoxic activity for a copper(II)-piroxicam complex.
    Cini R; Tamasi G; Defazio S; Hursthouse MB
    J Inorg Biochem; 2007 Aug; 101(8):1140-52. PubMed ID: 17592742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX.
    Elkady M; Nieß R; Schaible AM; Bauer J; Luderer S; Ambrosi G; Werz O; Laufer SA
    J Med Chem; 2012 Oct; 55(20):8958-62. PubMed ID: 22992107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandin E(2) synthase inhibition as a therapeutic target.
    Iyer JP; Srivastava PK; Dev R; Dastidar SG; Ray A
    Expert Opin Ther Targets; 2009 Jul; 13(7):849-65. PubMed ID: 19530988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PGE synthase inhibitors as an alternative to COX-2 inhibitors.
    Jachak SM
    Curr Opin Investig Drugs; 2007 May; 8(5):411-5. PubMed ID: 17520870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.